Mary Kerr, formerly global franchise leader for infectious diseases at GlaxoSmithKline Plc, has been appointed chief executive of NeRRe Therapeutics, effective early October. An experienced executive, Dr Kerr was also a founding member in the executive team of ViiV Healthcare, which is developing medicines for HIV. Founded in December 2012, NeRRe is developing a portfolio of NK receptor antagonist acquired from GSK that are thought to have potential in a broad range of indications.
NeRRe announced the appointment on 23 September 2015.
Copyright 2015 Evernow Publishing Ltd